Prof. Dr. med.
Christoph Renner
Hirslanden Cancer Institute, Zurich
CLL in 2026
Navigating New Treatment Choices
From new evidence to the right choice: guideline updates, AMPLIFY in depth and case-based decisions in first-line CLL.
Quickfacts
- November 26, 2026
- 17:30–19:10
- Webinar
- English
- HematologyOncology
- Credits requested: SSMO | SSH
Treatment options for chronic lymphocytic leukemia (CLL) continue to evolve. New study data and updated recommendations are shaping decisions about first-line therapy.
Join renowned experts from Zurich, Lucerne and Berlin for a practical review of the latest EHA guideline updates and a closer look at the AMPLIFY data. Using clinical case examples, the speakers will discuss how to choose a treatment strategy for individual patients in everyday practice.
The webinar will conclude with an interactive discussion of a key question in first-line treatment: continuous or fixed-duration therapy?
| 17:30 17:35 | WelcomeProf. Dr. med. Christoph Renner |
| 17:35 18:00 | EHA Guidelines NewsDr. med. Michael Gregor |
| 18:00 18:25 | AMPLIFY: Data Deep DiveProf. Dr. med. Frederik Damm |
| 18:25 18:50 | Case-Based Patient Selection in Daily PracticeDipl. Ärztin Young-Lan Song |
| 18:50 19:10 | Interactive Expert DiscussionContinuous vs. Fixed Duration Treatment in 1L CLL Q&A with all participants |
Chair
Prof. Dr. med.
Experts
Prof. Dr. med.
Frederik Damm
Charité, Berlin
Dipl. Ärztin
Young-Lan Song
Stadtspital Zürich
Dr. med.
Michael Gregor
Luzerner Kantonsspital
